JP2018534256A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534256A5
JP2018534256A5 JP2018515823A JP2018515823A JP2018534256A5 JP 2018534256 A5 JP2018534256 A5 JP 2018534256A5 JP 2018515823 A JP2018515823 A JP 2018515823A JP 2018515823 A JP2018515823 A JP 2018515823A JP 2018534256 A5 JP2018534256 A5 JP 2018534256A5
Authority
JP
Japan
Prior art keywords
human
compound
medicament
neoplastic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515823A
Other languages
English (en)
Japanese (ja)
Other versions
JP6853539B2 (ja
JP2018534256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053815 external-priority patent/WO2017053990A1/en
Publication of JP2018534256A publication Critical patent/JP2018534256A/ja
Publication of JP2018534256A5 publication Critical patent/JP2018534256A5/ja
Application granted granted Critical
Publication of JP6853539B2 publication Critical patent/JP6853539B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515823A 2015-09-24 2016-09-26 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法 Expired - Fee Related JP6853539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232377P 2015-09-24 2015-09-24
US62/232,377 2015-09-24
PCT/US2016/053815 WO2017053990A1 (en) 2015-09-24 2016-09-26 Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Publications (3)

Publication Number Publication Date
JP2018534256A JP2018534256A (ja) 2018-11-22
JP2018534256A5 true JP2018534256A5 (enExample) 2019-11-07
JP6853539B2 JP6853539B2 (ja) 2021-03-31

Family

ID=58387539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515823A Expired - Fee Related JP6853539B2 (ja) 2015-09-24 2016-09-26 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法

Country Status (7)

Country Link
US (3) US10995068B2 (enExample)
EP (1) EP3352753A4 (enExample)
JP (1) JP6853539B2 (enExample)
CN (1) CN108366990B (enExample)
CA (1) CA2999177A1 (enExample)
MX (1) MX394367B (enExample)
WO (1) WO2017053990A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009731A2 (en) 2013-07-15 2015-01-22 The Regents Of The University Of California Azacyclic constrained analogs of fty720
CN108366990B (zh) 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
EP3703653A4 (en) 2017-11-03 2021-09-08 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS
US20210261583A1 (en) * 2018-06-14 2021-08-26 The Regents Of The University Of California Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
US20220409617A1 (en) * 2019-11-13 2022-12-29 The Regents Of The University Of California Drug Formulations and Methods of Treatment for Metabolic Disorders
PH12022551623A1 (en) 2020-01-13 2023-11-29 Verge Analytics Inc Substituted pyrazolo-pyrimidines and uses thereof
CN116617221B (zh) * 2022-02-11 2025-06-17 复旦大学 Trpml1特异性小分子激动剂ml-sa1在制药中的用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3931155A (en) 1973-04-25 1976-01-06 Richardson-Merrell Inc. Process for preparing 2-azacycloalkylmethyl ketones
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
EP1256589A3 (en) 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
EP2253639A1 (en) 1997-09-12 2010-11-24 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ES2382807T3 (es) 2003-08-28 2012-06-13 Takeshi Imanishi Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US20050256056A1 (en) 2003-12-05 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer University Of California Peptide inhibitors of HIV
US20070258970A1 (en) 2003-12-09 2007-11-08 Robert Blumenthal Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
WO2005122379A2 (en) 2004-05-27 2005-12-22 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
WO2006020951A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
US7772406B2 (en) 2005-10-31 2010-08-10 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
US7968733B2 (en) 2006-06-06 2011-06-28 Gifu University Pyrrolidine analogue for preventing neurogenic pain and method for production thereof
US20080070866A1 (en) 2006-08-01 2008-03-20 Praecis Pharmaceuticals Incorporated Chemical compounds
CN101506164A (zh) 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
EP2120575A4 (en) 2006-12-21 2011-04-27 Abbott Lab AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
WO2008097819A2 (en) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Chemical compounds
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
ES2439591T3 (es) 2007-08-15 2014-01-23 Isis Pharmaceuticals, Inc. Análogos de ácido nucleico de tetrahidropirano
WO2009053481A1 (en) 2007-10-25 2009-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for modulating nk and t cell trafficking
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009106599A2 (en) 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
UA106591C2 (uk) 2008-07-23 2014-09-25 Тамара Алєксандровна Віткалова Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2012074960A2 (en) 2010-11-29 2012-06-07 The Ohio State University Research Foundation Fty720-derived anticancer agents
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
WO2014118556A2 (en) 2013-01-31 2014-08-07 Research Foundation Of The City University Of New York Selective inhibitors and allosteric activators of sphingosine kinase
TWI613182B (zh) * 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
BR112015027319A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Métodos e composições para modular a expressão de apolipoproteína (a)
WO2015009731A2 (en) 2013-07-15 2015-01-22 The Regents Of The University Of California Azacyclic constrained analogs of fty720
US10119136B2 (en) 2014-01-09 2018-11-06 Alnylam Pharmaceuticals, Inc. RNAi agents modified at the 4′-C position
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
JP2018518522A (ja) 2015-06-23 2018-07-12 ケース ウエスタン リザーブ ユニバーシティ 癌を治療するための組成物及び方法
CN108366990B (zh) 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
US20210261583A1 (en) 2018-06-14 2021-08-26 The Regents Of The University Of California Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
WO2021062168A1 (en) 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
US20220409617A1 (en) 2019-11-13 2022-12-29 The Regents Of The University Of California Drug Formulations and Methods of Treatment for Metabolic Disorders
WO2021236389A2 (en) 2020-05-16 2021-11-25 Bond Jason R Treatment of known and unknown viral infection with lipid agents
WO2022094615A1 (en) 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
US20240066006A1 (en) 2020-12-17 2024-02-29 The Regents Of The University Of California Antiviral Compounds and Applications Thereof

Similar Documents

Publication Publication Date Title
JP2018534256A5 (enExample)
Nagahashi et al. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer
EP3452448B1 (en) Modulators of the integrated stress pathway
JP6066421B2 (ja) 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法
JP2022017295A5 (enExample)
Lozier et al. Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma
EP4045498B1 (en) Broad spectrum anti-cancer compounds
JP2016506916A5 (enExample)
JP2012500197A5 (enExample)
JP2012530779A5 (enExample)
JP2019532080A5 (enExample)
EP3307728A1 (en) Combination therapy of transcription inhibitors and kinase inhibitors
US20250009736A1 (en) Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
JP2017534583A5 (enExample)
JP2020517707A5 (enExample)
JP2016529285A5 (enExample)
JP2013529219A (ja) ホスファプラチン、及び癌治療のためのそれらの使用
JP2022500408A (ja) エンザスタウリンとｂｔｋの阻害剤との組合せおよびその使用
JP2019506392A5 (enExample)
JP2022508935A (ja) がん治療における免疫モジュレーションのための組合せ
Tai et al. Sepsis increases perioperative metastases in a murine model
JP2022500497A (ja) がん治療で用いる５−アセトアミドメチルオキサゾリジノン誘導体
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
JP2012524070A5 (enExample)